$PFE (Pfizer Inc.)

$PFE {{ '2015-12-08T18:49:03+0000' | timeago}} • Announcement

$PFE said the U.S. FDA granted a priority review status for a supplemental new drug application for XALKORI (crizotinib) for treatment of ROS1-positive tumors in patients with non-small cell lung cancer. XALKORI received breakthrough therapy designation by the FDA for this indication in Apr. 2015. The likely FDA action date is April 2016.

$PFE {{ '2017-11-17T11:53:03+0000' | timeago}} • Announcement

The US FDA has approved a new use for $PFE’s cancer drug SUTENT. The drug was approved as an adjuvant in renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney).

$PFE {{ '2017-11-13T15:41:23+0000' | timeago}} • Announcement

$PFE has named Albert Bourla as COO effective Jan. 1, 2018. Also effective Jan. 1, John Young, Group President, Pfizer Essential Health will become Group President, Pfizer Innovative Health. Angela Hwang, Global President and General Manager for Pfizer Inflammation & Immunology will succeed John Young as Group President, Pfizer Essential Health.

$PFE {{ '2017-11-07T13:59:46+0000' | timeago}} • Webcast

$PFE welcomes the potential changes in drug distribution models. With $AMZN considering an entry into the pharmacy space, CEO Ian Read on the company's 3Q17 earnings call said, “Any system of distribution that can cut costs and get a wide availability of products to patients is something that the whole industry would be interested.”

$PFE {{ '2017-11-07T13:49:05+0000' | timeago}} • Webcast

$PFE’s Innovative Health business had strong 3Q17, driven by continued growth of key brands, including Ibrance and Eliquis globally and Xtandi, Lyrica, Xeljanz and Chantix in the US. On the other hand, Essential Health business saw revenue declining in the quarter, but had strong operational growth in emerging markets and in biosimilars portfolio.

$PFE {{ '2017-10-31T14:38:09+0000' | timeago}} • Announcement

$PFE's Innovative Health division, which sells newer, patent-protected medicines, posted an 11% increase in revenue for 3Q17, while Essential Health, that sells older drugs, fell 12%. The company lifted its FY17 EPS forecast to $2.58-2.62 from the previous range of $2.54-2.60, with revenue ranging between $52.4Bil and $53.1Bil.

$PFE {{ '2017-10-31T14:24:43+0000' | timeago}} • Announcement

With slightly higher sales and lower one-time charges, $PFE saw its profit double for 3Q17 to $2.8Bil, or $0.47 per share, from $1.35Bil, or $0.22 per share, a year ago. Revenue edged up nearly 1% to $13.2Bil, driven by higher sales from most of its key new drugs, including cancer medicine Ibrance that grew 60% YoY.

$PFE {{ '2017-10-31T12:07:05+0000' | timeago}} • Infographic

$PFE Pfizer Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$JNJ {{ '2017-10-17T19:25:16+0000' | timeago}} • Webcast

$JNJ said, "The key factor to Remicade being successful is physicians and patients have a high confidence in it based on experience that they don't want to switch to an alternative." The company was responding to a question on rival $PFE's lawsuit against it for allegedly using unfair means to protect Remicade from competitors.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$LLY {{ '2017-09-28T21:06:48+0000' | timeago}} • Announcement

FDA approves $LLY's breast cancer drug Verzenio (abemaciclib), which will compete with $PFE's Ibrance and $NVS' Kisqali drugs. Verzenio works by blocking certain molecules involved in promoting the growth of cancer cells. The National Cancer Institute estimated that approximately 252,710 women will be diagnosed with breast cancer this year.

$PFE {{ '2017-09-27T12:44:41+0000' | timeago}} • Announcement

$PFE declared 4Q17 dividend of $0.32 per share, payable Dec. 1, 2017, to shareholders of record at the close of business on Nov. 10, 2017. This cash dividend will be the 316th consecutive quarterly dividend paid by the company.

$PFE {{ '2017-09-27T12:19:24+0000' | timeago}} • Announcement

$PFE receives approval for BAVENCIO to treat Merkel cell carcinoma (MCC), a rare type of skin cancer, in Japan. This is the first-ever treatment indicated for curatively unresectable MCC and first anti-PD-L1 to be available in Japan.

$PFE {{ '2017-09-20T18:14:48+0000' | timeago}} • Announcement

$PFE filed a lawsuit against $JNJ over anticompetitive practices. The lawsuit alleges J&J violated federal antitrust laws by signing exclusionary contracts with health insurers, hospitals and doctor groups to ensure its medicine Remicade was given preferential treatment over Pfizer's new biosimilar Inflectra.

$MYL {{ '2017-09-08T21:46:48+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. Pfizer is continuing to work with the FDA to resolve the points raised in the warning letter regarding Pfizer’s manufacturing of the EpiPen products and Mylan will do whatever it can to support this process.

$MYL {{ '2017-09-08T21:46:14+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. The letter was issued in connection with FDA's inspection of Pfizer’s pharmaceutical manufacturing facility located in Brentwood, Missouri, where the EpiPen products are manufactured.

$PFE {{ '2017-08-29T14:05:59+0000' | timeago}} • Announcement

$PFE and $BMY presented investigational Eliquis data for patients with non-valvular atrial fibrillation undergoing cardioversion. The outcomes measured in EMANATE, a Phase 4 clinical trial, were the occurrence of acute stroke, systemic embolism, major bleeding, clinically relevant non-major bleeding and all-cause death.

$PFE {{ '2017-08-17T19:23:27+0000' | timeago}} • Announcement

The US FDA has approved $PFE's rare blood cancer drug BESPONSA. The U.S. labeling for BESPONSA includes a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease (VOD) and increased risk of post-HSCT non-relapse mortality.

$PFE {{ '2017-08-01T18:57:28+0000' | timeago}} • Webcast

$PFE expects five different potential blockbuster approvals in Oncology division and three potential blockbusters in Vaccines over the next five years. In addition, the company has 14 distinct biosimilar assets in the pipeline, eight of which are in mid-to-late stage development and six assets are in the early stage.

$PFE {{ '2017-08-01T18:56:05+0000' | timeago}} • Webcast

Over the next five years, $PFE projects the potential for about 25 to 30 approvals, of which up to 15 have the potential to be blockbusters. The company expects to receive approval for half of those potential blockbusters by 2020.

$PFE {{ '2017-08-01T14:15:55+0000' | timeago}} • Announcement

Top sellers including Lyrica, Ibrance and Eliquis produced higher sales, helping lift sales from $PFE’s Innovative Health segment by 8% in 2Q17. The company's Essential Health segment had sales dip 14% mostly due to few products losing marketing exclusivity. Sales of rheumatoid arthritis treatment Enbrel tumbled 20% on competition from biosimilars.

Recent Transcripts

BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
PRGO (Perrigo Company Public Limited Company)
Thursday, November 9 2017 - 1:00pm
OPK (Opko Health, Inc.)
Wednesday, November 8 2017 - 9:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
VCEL (Vericel Corporation)
Tuesday, November 7 2017 - 1:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
DRRX (DURECT Corporation)
Wednesday, November 1 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
ARRY (Array BioPharma Inc.)
Tuesday, October 31 2017 - 1:00pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
CYTK (Cytokinetics, Incorporated)
Thursday, October 26 2017 - 8:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, October 26 2017 - 8:30pm
ALGN (Align Technology Inc.)
Thursday, October 26 2017 - 8:30pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
AMGN (Amgen Inc)
Wednesday, October 25 2017 - 9:00pm

AlphaGraphics you may like